22316-50-3

Upstream product

• 119-75-5 2-nitro-N-phenylaniline 
• 174181-40-9 N-(2-nitrophenyl)-N-phenylmalonamic acid methyl ester 
• 534-85-0 N-phenyl-1,2-benzenediamine 
• 36242-47-4 N-carbethoxy acetyl N-phenyl o-phenylene diamine 
• 194278-28-9 N-(2-aminophenyl)-N-phenylmalonamic acid methyl ester 

Downstream Products

• 141277-89-6 1,3-Dihydro-4-morpholino-1-phenyl-2H-1,5-benzodiazepin-2-one 
• 141277-91-0 4-<4-(Ethoxycarbonyl)-1-piperazinyl>-1,3-dihydro-1-phenyl-2H-1,5-benzodiazepin-2-one 
• 23954-67-8 1-N-butyl-2,4-dioxo-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151620-51-8 2,4-dioxo-1-N-(3-methylbut-1-yl)-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151386-09-3 1-[2-(1-adamantyl)ethyl]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151385-92-1 2,4-dioxo-5-N-phenyl-1-N-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151385-95-4 1-N-(adamant-1-ylmethyl)-2,4-dioxo-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151386-02-6 1-N-(3,3-dimethylbut-1-yl)-2,4-dioxo-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151386-12-8 1-N-(2,3-dimethylbut-1-yl)-2,4-dioxo-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 22316-24-1 1-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-2,4-dione 
• 174180-99-5 N-Cyclopropyl-2-(2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl)-N-phenyl-acetamide 
• 182435-98-9 1-phenyl-5-(2-propyl)-1,5-benzodiazepin-2,4-dione 
• 174180-97-3 3-[1-(Cyclopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5,tetrahydro-1H-benzo[b][1,4]diazepin-3-ylmethyl]-indazole-1-carboxylic acid tert-butyl ester 
• 174181-06-7 3-{1-[(tert-Butyl-phenyl-carbamoyl)-methyl]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-ylmethyl}-indazole-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists

We previously described a series of 3-(1H-indazol-3-ylmethyl)-1,5- benzodiazepine CCK-A agonists exemplified by compound 1 (GW 5823), which is the first reported binding selective CCK-A full agonist demonstrating oral efficacy in a rat feeding model. In this report we describe analogs of compound 1 designed to explore changes to the CS and N1 pharmacophores and their effect on agonist activity and receptor selectivity. Agonist efficacy in this series was affected by stereoelectronic factors within the C3 moiety. Binding affinity for the CCK-A vs CCK-B receptor showed little dependence on the structure of the C3 moiety but was affected by the nature of the second substituent at CS. Structure-activity relationships at the N1- anilidoacetamide 'trigger' moiety within the C3 indazole series were also investigated. Both agonist efficacy and binding affinity within this series were modulated by variation of substituents on the Nl-anilidoacetamide moiety. Evaluation of several analogs in an in vivo mouse gallbladder emptying assay revealed compound 1 to be the most potent and efficacious of all the analogs tested. The pharmacokinetic and pharmacodynamic profile of 1 in rats is also discussed.

N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides

This invention is concerned with novel compounds represented by structural formula I STR1 which are useful in the treatment of arrhythmia.

1,5-Benzodiazepine-2,4-diones

This invention relates to substituted 1,5-benzodiazepines having the formula SPC1 Wherein R1 and R2 are hydrogen or substituents, R3 is hydrogen or substituents, R4 is methyl or aryl group, As well as the process of producing the same. The compounds of the invention are tranquillizing analgesic, antipyretic and anti-inflammatory agents.